==========================================================================================
MEDIKAMENT 1: Erlotinib (EGFR Tyrosine Kinase Inhibitor)
==========================================================================================

Erwartete Biomarker:
  Primary: MUT__EGFR (aktivierende Mutationen → Sensitivität)
  Secondary: CNV__EGFR, TPM__EGFR (Amplifikation/Expression)
  Resistance: MUT__KRAS, MUT__BRAF (downstream activation)
  Bypass: TPM__MET, CNV__MET (alternative signaling)

Testing unimodality for all features...

Generating 200 complementary pairs...

Running CPSS with B=200 pairs...
  Using q_rf=48 (increased from q=96 for better biomarker recovery)
